Calypte gets HIV test order in Burkina Faso:
This article was originally published in Clinica
Alameda, California-based Calypte Biomedical has received its first West African order for its urine-based HIV-1 antibody test, for use in Burkina Faso, which has a population of some 12 million people, with an adult HIV rate of 6.5%. "We would expect that as word of favourable experience with Calypte's urine HIV test spreads, this initial order should drive future sales, not only in Burkina, but elsewhere in the region," said Tony Cataldo, chairman. The company is using a Burkinabe distributor and hopes to expand into Benin, Togo, Ivory Coast, Mali and Niger over the next year.
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.